From the blog

That "Overmethylation" Theory Going Around: What the Evidence Actually Shows

An illustrated DNA double helix with methyl groups attached

Quick answers

Is "overmethylation syndrome" a real medical diagnosis?
No. It does not appear in peer-reviewed clinical literature as a defined, validated condition. The closest official position from clinical genetics runs the other way: for a related gene, MTHFR, the American College of Medical Genetics and Genomics has found minimal clinical value in testing it for clotting risk and recommended against ordering it routinely [4].
Is the COMT gene real, and does it actually affect dopamine?
Yes, the underlying biochemistry is real. The COMT Val158Met variant changes how quickly the COMT enzyme breaks down dopamine, and human brain-imaging studies confirm that carriers of the slower-acting variant process dopamine differently [1]. But the measurable effect on things like mental focus is small, not the dramatic personality difference sometimes described online [2].
Do methylfolate or methyl-B12 supplements actually cause anxiety or panic attacks?
No published clinical trial or case series shows this. The largest randomized trials of L-methylfolate, the exact methylated folate ingredient in question, found it as well tolerated as placebo, with no unusual rate of anxiety-type side effects [5, 6]. Individual reports of feeling "wired" after starting a B-vitamin exist, mostly in patient and practitioner forums, but the specific chain of brain chemistry often used to explain them has never been tested.

You may have come across a version of this online: a confident, detailed explanation for why methylfolate (the active form of folate, also called 5-MTHF) or methylcobalamin (an active form of vitamin B12) can supposedly trigger sudden anxiety, panic attacks, ADHD-like scatter, or obsessive, looping thoughts. The explanation usually centers on a gene called COMT and a process called "overmethylation." It is presented as settled biochemistry, with a fix: switch to non-methylated versions of the same vitamins, and the symptoms are said to resolve within days.

Some of the biochemistry behind that story is real and worth understanding. Most of the specific chain of cause and effect used to explain your symptoms is not something anyone has actually tested. Here is where the line falls.

What is COMT, and what part of this is real?

COMT stands for catechol-O-methyltransferase, an enzyme your body uses to break down dopamine and related brain chemicals, norepinephrine and epinephrine (also known as noradrenaline and adrenaline), once they have done their job in the brain. A common genetic variant, often shorthanded as "fast" or "slow" COMT, changes how quickly this enzyme works. People with the slower-acting version are sometimes described online as running with naturally higher dopamine "on board."

That basic mechanism is real, though it is more complicated than the "more dopamine on board" framing suggests. Human brain-imaging research has confirmed that people carrying the slower-acting COMT variant process dopamine differently in circuits connecting the prefrontal cortex, the brain's planning and focus center, to deeper structures involved in making dopamine — but in that same research, carriers of the slower variant actually showed reduced dopamine synthesis in one of those deeper structures, not simply more dopamine everywhere [1]. What is much less settled is how large a real-world difference any of this makes. The largest meta-analysis on COMT and mental performance, pooling data from 12 studies and 1,910 people, found that people with the slower variant performed modestly better on a test of mental flexibility than people with the faster variant. The effect was real but small, 0.29 on the standardized scale researchers use to size these differences, and it did not hold up in a comparison group of people with schizophrenia [2]. That is a genuine, measurable effect. It is also a small one, nowhere near a decisive personality trait, and on its own it says nothing about anxiety, panic, or attention problems.

Where the "overmethylation" story runs past the evidence

The theory then builds outward from COMT into what is usually called an "overmethylation" reaction. The building blocks it uses are real. Your cells run on a molecule called SAMe (S-adenosylmethionine), which acts like a delivery truck for methyl groups, small chemical tags that enzymes attach to other molecules. COMT is one of several enzymes that use SAMe this way. So is PNMT, the enzyme that converts norepinephrine into epinephrine, and HNMT, the enzyme that breaks down histamine. Older laboratory research on this enzyme family, done in animal tissue rather than in people, confirms they draw on the same SAMe supply and can be blocked by related molecules [3].

The theory then chains these separate, real facts into one specific story: taking a methylfolate or methylcobalamin capsule floods your cells with SAMe, which overloads COMT, spills over into PNMT, produces a surge of adrenaline that a "slow COMT" system cannot clear fast enough, and the result is panic. A search of the published medical literature turns up no study, in humans, animals, or cells, that has actually tested this specific chain from vitamin dose to adrenaline surge to panic symptom. The same is true of several of the theory's other named mechanisms, including specific claims about receptor changes behind obsessive thinking and specific brain channels behind attention problems: each names a real area of neuroscience studied in very different contexts, none of them a B-vitamin supplement. Connecting several true facts into a specific story is not the same thing as testing whether that story is what actually happens in your body.

Is "overmethylation syndrome" an actual diagnosis?

No. It does not appear in peer-reviewed clinical or diagnostic literature as a defined, validated condition.

If anything, the official guidance from clinical genetics runs the other direction. MTHFR, a different gene involved in the same folate-processing pathway, has become a popular target for direct-to-consumer genetic testing, often marketed with similarly confident claims about methylation problems. The American College of Medical Genetics and Genomics, the professional body that sets practice standards for genetic testing in the United States, reviewed the evidence connecting MTHFR variants to clotting risk and concluded that testing for it has minimal clinical value, recommending against ordering it as part of a routine clotting-risk evaluation [4]. That is not proof that every claim built on methylation genes is wrong; the ACMG statement addresses a different gene and a different use case. It is a real signal from the people whose job is to evaluate this kind of evidence, and it leans skeptical, not confirmatory.

What do the real human trials on methylfolate actually say?

Here is the closest thing to a direct test. L-methylfolate, the same methylated folate at the center of this theory, has been studied in randomized, placebo-controlled trials, not for anxiety, but as an add-on treatment for depression that had not fully responded to an antidepressant. Two such trials, together enrolling over 200 people, tested this. The trial using a steady 15 mg daily dose found L-methylfolate improved depression symptoms significantly more than placebo; a related trial using a lower starting dose found no significant difference between groups. Across both, the researchers reported that L-methylfolate was well tolerated, with side effects occurring at about the same rate as with placebo [5]. A separate systematic review of nutrient treatments for depression, covering methylfolate along with several other supplements, reported no major adverse effects across the studies it examined, aside from minor digestive upset [6].

None of this proves no one ever feels anxious or wired after starting a B-vitamin. Trial averages can hide a reaction that only shows up in a smaller subgroup, and no trial has specifically sorted people by COMT genotype to see whether a "slow COMT" subgroup reacts differently. But this is real evidence, from controlled human trials of the actual ingredient in question, and it points the opposite direction from a common, predictable activation reaction. Framing the methylated vitamin as the specific, singular cause of these symptoms claims far more certainty than any published trial has produced.

What about folinic acid, hydroxocobalamin, and adenosylcobalamin?

The alternative forms this theory recommends are real vitamins with real, if different, uses.

Folinic acid (also called leucovorin or calcium folinate) genuinely is a folate form that does not require the MTHFR enzyme step methylfolate does. It has real trial evidence behind it, though for a different population than this theory targets: a randomized, placebo-controlled trial in 48 children with autism spectrum disorder and language delay found that high-dose folinic acid improved verbal communication compared with placebo, especially in children with a specific antibody marker, with no significant difference in side effects between groups [7]. Nobody has run the head-to-head trial this theory implies exists: folinic acid against methylfolate, in people who react badly to the methylated form.

Hydroxocobalamin is a genuinely different B12 form with well-established medical uses of its own. It is the standard antidote given intravenously for cyanide poisoning, and a small case series of 12 patients has explored it, again by IV and at doses far higher than any supplement bottle, for vasoplegic syndrome, a dangerous drop in blood pressure that occurs in an estimated 8 to 12 percent of cases using a heart-lung bypass machine during cardiac surgery, based on its real ability to bind and inactivate nitric oxide [8]. That chemistry is genuine. It has been studied in acute, critical-care medicine, at IV doses meant to treat a medical emergency, not as an oral supplement for calming everyday anxiety or "neuroinflammation," and nothing published tests it that way.

Adenosylcobalamin is likewise a real, distinct form of B12: it is specifically the form your mitochondria use for one particular reaction, while methylcobalamin is used for a separate reaction elsewhere in the cell. That division of labor is confirmed by research into rare inherited disorders of B12 metabolism: children born unable to make adenosylcobalamin alone develop a distinct, milder-to-severe pattern of methylmalonic acidemia depending on which gene is affected [9], while children unable to make both adenosylcobalamin and methylcobalamin develop a broader, more variable combined condition affecting both pathways at once [10]. That is accurate biochemistry. There is no published study comparing adenosylcobalamin to methylcobalamin for anxiety or attention symptoms in anyone.

None of this means these alternative forms are useless, or that switching would never help anyone feel better. It means the specific comparison this theory is built on, methylated B-vitamins causing a testable psychiatric reaction that non-methylated forms reliably fix, has not actually been run.

So what should you actually do?

If you notice you feel anxious, wired, or unable to focus after starting a B-vitamin or a new supplement, that is a real observation worth taking seriously, regardless of whether the mechanism offered to explain it holds up. Stop the supplement, see whether the feeling resolves, and bring what you noticed to a clinician who can look at your fuller picture, including other medications, your diet, and your actual lab values, rather than trying to self-diagnose a genetic pathway from an online thread.

If you are curious about your own COMT or MTHFR genotype, know what you are actually buying: a real gene with a real, modest, and only partly understood effect on brain chemistry, not a diagnosis, and not, on the current evidence, an explanation for a specific psychiatric syndrome with a specific vitamin-swap cure.

I go deeper on supplement claims, genetic testing, and the root-cause approach in Bad Medicine Blues. Read a free chapter.

Sources

  1. Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. Midbrain dopamine and prefrontal function in humans- interaction and modulation by COMT genotype. Nat Neurosci. 2005;8(5):594-596. doi.org/10.1038/nn1438
  2. Barnett JH, Jones PB, Robbins TW, Müller U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function- a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry. 2007;12(5):502-509. doi.org/10.1038/sj.mp.4001973
  3. Borchardt RT, Huber JA, Wu YS. Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 4. Further modifications of the amino and base portions of S-adenosyl-L-homocysteine. J Med Chem. 1976;19(9):1094-1099. doi.org/10.1021/jm00231a003
  4. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline- lack of evidence for MTHFR polymorphism testing. Genet Med. 2013;15(2):153-156. doi.org/10.1038/gim.2012.165
  5. Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression- results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267-1274. doi.org/10.1176/appi.ajp.2012.11071114
  6. Sarris J, Murphy J, Mischoulon D, et al. Adjunctive Nutraceuticals for Depression- A Systematic Review and Meta-Analyses. Am J Psychiatry. 2016;173(6):575-587. doi.org/10.1176/appi.ajp.2016.15091228
  7. Frye RE, Slattery J, Delhey L, et al. Folinic acid improves verbal communication in children with autism and language impairment- a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2018;23(2):247-256. doi.org/10.1038/mp.2016.168
  8. Seelhammer TG, Plack D, Nei S, Wittwer E, Nelson J, Nabzdyk CGS. Extended duration infusion of high-dose hydroxocobalamin for vasoplegic syndrome following cardiac surgery. Heart Lung. 2021;50(2):173-176. doi.org/10.1016/j.hrtlng.2020.11.003
  9. Vatanavicharn N, Champattanachai V, Liammongkolkul S, et al. Clinical and molecular findings in Thai patients with isolated methylmalonic acidemia. Mol Genet Metab. 2012;106(4):424-429. doi.org/10.1016/j.ymgme.2012.05.012
  10. Carrillo-Carrasco N, Chandler RJ, Venditti CP. Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. J Inherit Metab Dis. 2012;35(1):91-102. doi.org/10.1007/s10545-011-9364-y

← All posts

Free — no purchase needed

Get the Companion Workbook, free.

Join the reader list and I will send you the Companion Workbook and Quick-Start Checklist. Simple tools to turn what you are reading into daily practice, before you spend a penny on anything.

You'll get the workbook and checklist right away, then an occasional grounded note about root-cause health. No spam, no selling your address, and every email has a one-click unsubscribe.